{"id":47073,"date":"2026-07-29T13:00:00","date_gmt":"2026-07-29T11:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=e13f35763cb881e06138b65e3cd373f4"},"modified":"2026-07-29T13:00:00","modified_gmt":"2026-07-29T11:00:00","slug":"evinova-launches-strategic-partnership-with-merck-kgaa-darmstadt-germany-to-define-the-future-of-clinical-development","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=47073","title":{"rendered":"Evinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical Development"},"content":{"rendered":"

\nEvinova\u2019s full Study Designer with AI suite will be leveraged by Merck KGaA, Darmstadt, Germany to shape future product innovations and accelerate industry-wide transformation<\/i><\/p><\/a><\/a>

BAAR, Switzerland--(BUSINESS WIRE)--Evinova, a global leader in AI-native clinical development technology, today announced a new multi-year strategic collaboration to accelerate global clinical development with Merck KGaA, Darmstadt, Germany, a leading science and technology company. Merck KGaA, Darmstadt, Germany will adopt the end-to-end capabilities of the Evinova AI-Native platform<\/a> covering all modules of study design, document authoring, and downstream automation to significantly reduce time, costs, and operational bottlenecks in clinical development. Together, the companies aim to revolutionize the next era of AI-driven R&D transformation.<\/p>

\n\u201cMerck KGaA, Darmstadt, Germany\u2019s forward thinking and bold approach to transforming clinical development end-to-end raises the bar for the industry, making them an exceptional partner for Evinova\u2019s efforts,\u201d said Cristina Duran, President of Evinova. \u201cWith a seat on Evinova\u2019s Strategic Roadmap Steering Committee, Merck KGaA, Darmstadt, Germany will help, and together we will push the next frontier of clinical development to accelerate the delivery of high-quality medicines to patients.\u201d<\/p>

\nSetting a New Standard in Intelligent Clinical Development<\/b><\/p>

\nUnder the terms of the agreement, Merck KGaA, Darmstadt, Germany will gain priority access to Evinova\u2019s continuously advancing suite of AI-native capabilities, including:<\/p>